Business
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI, January 10, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 214,331 shares of common stock. Awards were made to seventeen new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Co
About this update from Summit Therapeutics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":292,"url":"https://media.zenfs.com/en/business-wire.com/96317f83b837e2f1b8acf58aa395ce4f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XNjxpNzZglWLGCk32o0tOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU4NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/96317f83b837e2f1b8acf58aa395ce4f","width":480,"height":292}},"lazy":false},{"type":"text","content":"MIAMI, January 10, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 214,331 shares of common stock. Awards were made to seventeen new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company’s Compensation Committee. The inducement awards were granted on January 6, 2026. The options have a ten (10) year term and an exercise price of $18.66 per share, the closing price per share of the Company’s common stock as reported by Nasdaq on January 6, 2026. The options were granted from a pool of equity incentives reserved by the Compensation Committee on January 22, 2025 for issuance as inducements to new employees in accordance with Nasdaq Listing Rule 5635(c)(4).","length":1004,"tagName":"p"},{"type":"text","content":"The options awarded to the recipients are subject to vesting in equal annual installments over a four-year period. The options awarded are subject to the terms of a stock option agreement to be executed by the recipient of the grant.","length":233,"tagName":"p"},{"type":"text","content":"About Summit Therapeutics","length":25,"tagName":"p"},{"type":"text","content":"Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.","length":318,"tagName":"p"},{"type":"text","content":"Summit was founded in 2003 and our shares are listed on the ...